{"DataElement":{"publicId":"2685408","version":"1","preferredName":"AIDS Malignancy Consortium Patient Inclusion Clinical Trial Eligibility Criteria 052 Type","preferredDefinition":"the type of element of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by NCI.","longName":"AMC_PT_I_CTEC_052_TP","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2518231","version":"1","preferredName":"AIDS Malignancy Consortium Patient Inclusion Clinical Trial Eligibility Criteria","preferredDefinition":"information relating to the elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial of a person who receives medical attention, care, or treatment in a clinical trials cooperative group supported by NCI.","longName":"AMC_PT_INCL_CTEC","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2518228","version":"1","preferredName":"AIDS Malignancy Consortium Patient","preferredDefinition":"Established in 1995 to carry out Phase I and II studies of innovative therapies for AIDS malignancies.:A person who requires medical care.","longName":"C19707:C16960","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AIDS Malignancy Consortium","conceptCode":"C19707","definition":"Established in 1995 to carry out Phase I and II studies of innovative therapies for AIDS malignancies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Patient","conceptCode":"C16960","definition":"A person who receives medical attention, care, or treatment, or who is registered with medical professional or institution with the purpose to receive medical care when necessary.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC96D39-08C6-6793-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2518229","version":"1","preferredName":"Inclusion Clinical Trial Eligibility Criteria","preferredDefinition":"The addition of somebody or something to, or the presence of somebody or something in, a group or mixture, particularly, a passive, usually temporary, product of cell activity within the cytoplasm or nucleus.:Elements of a personal medical history which are necessary to allow an individual to participate in a specific clinical trial.","longName":"C25532:C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Inclusion Criteria","conceptCode":"C25532","definition":"Medical and/or social characteristics which are necessary for a subject to be allowed to participate in a clinical study, as outlined in the study protocol. Meeting inclusion criteria is not a sufficient condition for entry or recruitment of a subject into the study. Characteristics limiting the eligibility of a subject for the clinical study must be considered.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC96D39-08D4-6793-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-09-06","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"ONEDATA","dateModified":"2006-09-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1CC977E8-B49D-6863-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-05","endDate":null,"createdBy":"SHIDED","dateCreated":"2006-09-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2685409","version":"1","preferredName":"052 Inclusion Clinical Trial Eligibility Criteria Type","preferredDefinition":"the type of clinical trial eligibility inclusion criteria for an AIDS Malignancy Consortium 052 protocol.","longName":"052_INCL_CTEC_TP","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"220","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Participant's age (in years)","valueDescription":"Participant's age (in years)","ValueMeaning":{"publicId":"2649471","version":"1","preferredName":"Participant's age (in years)","longName":"2649471","preferredDefinition":"Participant's age (in years)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"326557B2-97F1-3BD4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BAE87C8-35C5-1091-E044-0003BA3F9857","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"ONEDATA","dateModified":"2007-10-04","deletedIndicator":"No"},{"value":"Does the participant have the ability and willingness to give informed consent","valueDescription":"Does the participant have the ability and willingness to give informed consent","ValueMeaning":{"publicId":"2649472","version":"1","preferredName":"Does the participant have the ability and willingness to give informed consent","longName":"2649472","preferredDefinition":"Does the participant have the ability and willingness to give informed consent","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"32655A77-933F-3C34-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BAE87C8-35D0-1091-E044-0003BA3F9857","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"ONEDATA","dateModified":"2007-10-04","deletedIndicator":"No"},{"value":"Date of informed consent","valueDescription":"Date of informed consent","ValueMeaning":{"publicId":"2685412","version":"1","preferredName":"Date of informed consent","longName":"2685412","preferredDefinition":"Date of informed consent","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BAF65BD-CE07-106D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BAE87C8-35E1-1091-E044-0003BA3F9857","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"ONEDATA","dateModified":"2007-10-04","deletedIndicator":"No"},{"value":"Does the participant have documentation of HIV-1 infection by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry","valueDescription":"Does the participant have documentation of HIV-1 infection by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry","ValueMeaning":{"publicId":"2685411","version":"1","preferredName":"Does the participant have documentation of HIV-1 infection by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry","longName":"2685411","preferredDefinition":"Does the participant have documentation of HIV-1 infection by any licensed ELISA test kit and confirmed by Western blot at any time prior to study entry","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BAF7DC5-AA12-12EC-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BAE87C8-35F3-1091-E044-0003BA3F9857","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"ONEDATA","dateModified":"2007-10-04","deletedIndicator":"No"},{"value":"Anal HPV DNA PCR result: Type 16; positive, negative Type 18; positive, negative","valueDescription":"Anal HPV DNA PCR result: Type 16; positive, negative Type 18; positive, negative","ValueMeaning":{"publicId":"2685410","version":"1","preferredName":"Anal HPV DNA PCR result: Type 16; positive, negative Type 18; positive, negative","longName":"2685410","preferredDefinition":"Anal HPV DNA PCR result: Type 16; positive, negative Type 18; positive, negative","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BAF70C3-FD21-1143-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BAE87C8-3605-1091-E044-0003BA3F9857","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"ONEDATA","dateModified":"2007-10-04","deletedIndicator":"No"},{"value":"Did the participant have a normal anal cytological results, or ASCUS/LSIL result, within 45 days prior to entry","valueDescription":"Did the participant have a normal anal cytological results, or ASCUS/LSIL result, within 45 days prior to entry","ValueMeaning":{"publicId":"2685420","version":"1","preferredName":"Did the participant have a normal anal cytological results, or ASCUS/LSIL result, within 45 days prior to entry","longName":"2685420","preferredDefinition":"Did the participant have a normal anal cytological results, or ASCUS/LSIL result, within 45 days prior to entry","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BAE8C82-F11D-09F5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BAF65BD-CE1E-106D-E044-0003BA3F9857","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"ONEDATA","dateModified":"2007-10-04","deletedIndicator":"No"},{"value":"Were the following hematologic parameters met and performed within 45 days prior to study entry: Absolute neutrophil count (>750 cells/mm^3); Hemoglobin (>=9.0 g/dL); Platelet count (>=100,000/ mm^3)","valueDescription":"Were the following hematologic parameters met and performed within 45 days prior to study entry: Absolute neutrophil count (>750 cells/mm^3); Hemoglobin (>=9.0 g/dL); Platelet count (>=100,000/ mm^3)","ValueMeaning":{"publicId":"2685416","version":"1","preferredName":"Were the following hematologic parameters met and performed within 45 days prior to study entry: Absolute neutrophil count (>750 cells/mm^3); Hemoglobin (>=9.0 g/dL); Platelet count (>=100,000/ mm^3)","longName":"2685416","preferredDefinition":"Were the following hematologic parameters met and performed within 45 days prior to study entry: Absolute neutrophil count (>750 cells/mm^3); Hemoglobin (>=9.0 g/dL); Platelet count (>=100,000/ mm^3)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BAE9183-0FF4-1075-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BAF65BD-CE30-106D-E044-0003BA3F9857","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"ONEDATA","dateModified":"2007-10-04","deletedIndicator":"No"},{"value":"Were the following laboratory parameters met and performed within 45 days prior to study entry: Creatinine (<=3 x ULN); AST (<=3 x ULN); ALT (<=3 x ULN); Bilirubin (total or direct) (<=2.5 x ULN)","valueDescription":"Were the following laboratory parameters met and performed within 45 days prior to study entry: Creatinine (<=3 x ULN); AST (<=3 x ULN); ALT (<=3 x ULN); Bilirubin (total or direct) (<=2.5 x ULN)","ValueMeaning":{"publicId":"2685415","version":"1","preferredName":"Were the following laboratory parameters met and performed within 45 days prior to study entry: Creatinine (<=3 x ULN); AST (<=3 x ULN); ALT (<=3 x ULN); Bilirubin (total or direct) (<=2.5 x ULN)","longName":"2685415","preferredDefinition":"Were the following laboratory parameters met and performed within 45 days prior to study entry: Creatinine (<=3 x ULN); AST (<=3 x ULN); ALT (<=3 x ULN); Bilirubin (total or direct) (<=2.5 x ULN)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BAE8FC4-61E7-12F6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BAF65BD-CE42-106D-E044-0003BA3F9857","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"ONEDATA","dateModified":"2007-10-04","deletedIndicator":"No"},{"value":"Karnofsky performance status (must be >=70 and assessed within 45 or fewer days prior to entry)","valueDescription":"Karnofsky performance status (must be >=70 and assessed within 45 or fewer days prior to entry)","ValueMeaning":{"publicId":"2685414","version":"1","preferredName":"Karnofsky performance status (must be >=70 and assessed within 45 or fewer days prior to entry)","longName":"2685414","preferredDefinition":"Karnofsky performance status (must be >=70 and assessed within 45 or fewer days prior to entry)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BAF70C3-FD31-1143-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BAF65BD-CE54-106D-E044-0003BA3F9857","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"ONEDATA","dateModified":"2007-10-04","deletedIndicator":"No"},{"value":"Is the participant receiving antiretroviral therapy","valueDescription":"Is the participant receiving antiretroviral therapy","ValueMeaning":{"publicId":"2685413","version":"1","preferredName":"Is the participant receiving antiretroviral therapy","longName":"2685413","preferredDefinition":"Is the participant receiving antiretroviral therapy","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BAE8C1B-D0C6-1234-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BAF65BD-CE66-106D-E044-0003BA3F9857","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"ONEDATA","dateModified":"2007-10-04","deletedIndicator":"No"},{"value":"Is the participant's screening CD4+ cell count >200 cells/mm^3","valueDescription":"Is the participant's screening CD4+ cell count >200 cells/mm^3","ValueMeaning":{"publicId":"2685426","version":"1","preferredName":"Is the participant's screening CD4+ cell count >200 cells/mm^3","longName":"2685426","preferredDefinition":"Is the participant's screening CD4+ cell count >200 cells/mm^3","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BAEA99A-2021-121F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BAE8C82-F144-09F5-E044-0003BA3F9857","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"ONEDATA","dateModified":"2007-10-04","deletedIndicator":"No"},{"value":"Is the participant's screening plasma HIV-1 RNA result (i.e. viral load) below the limit of detection (with the lower limit of detection 200 copies or less) or detectable but < 200 copies/ml","valueDescription":"Is the participant's screening plasma HIV-1 RNA result (i.e. viral load) below the limit of detection (with the lower limit of detection 200 copies or less) or detectable but < 200 copies/ml","ValueMeaning":{"publicId":"2685427","version":"1","preferredName":"Is the participant's screening plasma HIV-1 RNA result (i.e. viral load) below the limit of detection (with the lower limit of detection 200 copies or less) or detectable but < 200 copies/ml","longName":"2685427","preferredDefinition":"Is the participant's screening plasma HIV-1 RNA result (i.e. viral load) below the limit of detection (with the lower limit of detection 200 copies or less) or detectable but < 200 copies/ml","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BAF72B8-F8F8-127E-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BAE8C82-F156-09F5-E044-0003BA3F9857","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"ONEDATA","dateModified":"2007-10-04","deletedIndicator":"No"},{"value":"Has the participant received antiretroviral therapy continuously (i.e. no interruptions of antiretroviral therapy lasting longer then 7 days) for at least 6 months prior to entry","valueDescription":"Has the participant received antiretroviral therapy continuously (i.e. no interruptions of antiretroviral therapy lasting longer then 7 days) for at least 6 months prior to entry","ValueMeaning":{"publicId":"2685425","version":"1","preferredName":"Has the participant received antiretroviral therapy continuously (i.e. no interruptions of antiretroviral therapy lasting longer then 7 days) for at least 6 months prior to entry","longName":"2685425","preferredDefinition":"Has the participant received antiretroviral therapy continuously (i.e. no interruptions of antiretroviral therapy lasting longer then 7 days) for at least 6 months prior to entry","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BAEA66B-44FE-1223-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BAE8C82-F168-09F5-E044-0003BA3F9857","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"ONEDATA","dateModified":"2007-10-04","deletedIndicator":"No"},{"value":"Has the participant's antiretroviral therapy remained unchanged in the 30 days prior to entry","valueDescription":"Has the participant's antiretroviral therapy remained unchanged in the 30 days prior to entry","ValueMeaning":{"publicId":"2685424","version":"1","preferredName":"Has the participant's antiretroviral therapy remained unchanged in the 30 days prior to entry","longName":"2685424","preferredDefinition":"Has the participant's antiretroviral therapy remained unchanged in the 30 days prior to entry","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BAE8C82-F12D-09F5-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BAE8C82-F17A-09F5-E044-0003BA3F9857","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"ONEDATA","dateModified":"2007-10-04","deletedIndicator":"No"},{"value":"Is the participant's screening CD4+ cell count >=350 cells/mm^3 (within 90 days prior to entry)","valueDescription":"Is the participant's screening CD4+ cell count >=350 cells/mm^3 (within 90 days prior to entry)","ValueMeaning":{"publicId":"2685423","version":"1","preferredName":"Is the participant's screening CD4+ cell count >=350 cells/mm^3 (within 90 days prior to entry)","longName":"2685423","preferredDefinition":"Is the participant's screening CD4+ cell count >=350 cells/mm^3 (within 90 days prior to entry)","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BAE9CFC-F43A-1079-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BAE8C82-F18C-09F5-E044-0003BA3F9857","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"ONEDATA","dateModified":"2007-10-04","deletedIndicator":"No"},{"value":"Is the participant planning to remain off antiretroviral therapy within 28 weeks after entry","valueDescription":"Is the participant planning to remain off antiretroviral therapy within 28 weeks after entry","ValueMeaning":{"publicId":"2685428","version":"1","preferredName":"Is the participant planning to remain off antiretroviral therapy within 28 weeks after entry","longName":"2685428","preferredDefinition":"Is the participant planning to remain off antiretroviral therapy within 28 weeks after entry","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BAEB581-02CF-1063-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3BAEB655-3EBF-1315-E044-0003BA3F9857","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"ONEDATA","dateModified":"2007-10-04","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2177853","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"Type","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"C16D625D-02B6-1907-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-07-09","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2003-07-09","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BAF70C3-FD0B-1143-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"SHIDED","dateModified":"2011-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Inclusion Criteria","type":"Preferred Question Text","description":"Inclusion Criteria","url":null,"context":"CTEP"}],"origin":"AMC CRF:AIDS Malignancy Consortium Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3BAF65BD-CDE3-106D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-04","endDate":null,"createdBy":"SHIDED","dateCreated":"2007-10-04","modifiedBy":"CAMPBELB","dateModified":"2011-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}